BSX Stock Price - Boston Scientific Corp. Stock Quote (U.S.: NYSE) - MarketWatch

Open $31.97
Day Range 31.77 - 37.30
52 Week Range 24.54 - 37.30
Market Cap $44.08B
Shares Outstanding 1.38B
Public Float 1.38B
Beta 1.04
Rev. per Employee $319.52K
P/E Ratio 500.29
EPS $0.07
Yield n/a
Dividend n/a
Ex-Dividend Date n/a
Short Interest 16.64M 05/15/18
% of Float Shorted 1.21%
Average Volume 7.06M

5 Day	13.88%
1 Month	18.11%
3 Month	23.06%
YTD	41.13%
1 Year	25.30%

MarketWatch
Other Dow Jones

Boston Scientific, Stryker stock halted for news pending

Jun. 11, 2018 at 1:09 p.m. ET
by Tomi Kilgore

Boston Scientific gets takeover approach from Stryker

Jun. 11, 2018 at 12:29 p.m. ET
by Dana Mattioli

Boston Scientific's stock soars after report of buyout approach from Stryker

Shares of Boston Scientific Corp. shot up 8.3% toward a 13-year high in morning trade Monday, after The Wall Street Journal reported that the medical device company received a buyout approach medical technology products company Stryker Corp. . Stryker's stock slumped 3.3%. The WSJ report said it was unclear whether Boston Scientific was receptive to Stryker's approach. Boston Scientific's stock was trading at levels not seen since February 2005. At current prices, Boston Scientific had a market capitalization of $47.76 billion, while Stryker's market cap was $64.65 billion. Boston Scientific's stock has run up 24.4% over the past 12 months, while Stryker shares hve climbed 21.9% and the S&P 500 has gained 14.4%.

Jun. 11, 2018 at 10:50 a.m. ET
by Tomi Kilgore

Boston Scientific's stock soars 9.8% after WSJ report of Stryker's buyout approach

Jun. 11, 2018 at 10:41 a.m. ET
by Tomi Kilgore

Boston Scientific receives buyout approach from Stryker--WSJ

Jun. 11, 2018 at 10:40 a.m. ET
by Tomi Kilgore

Why this is ‘as good as it gets’ for the stock rally

Apr. 25, 2018 at 9:29 a.m. ET
by Barbara Kollmeyer

Boston Scientific profit rises 2.8%

Boston Scientific Corp. BSX Wednesday said profit rose 2.8% and raised its sales guidance for the year. The Massachusetts-based medical devices maker reported a profit of $298 million, or 21 cents a share, compared with $290 million, or 21 cents a share, for the same period last year. Excluding items, Boston Scientific reported a profit of 33 cents a share for the quarter.

Apr. 25, 2018 at 6:57 a.m. ET
by MarketWatch.com

Boston Scientific Q2 FactSet EPS consensus 35 cents; 2018 $1.37

Apr. 25, 2018 at 6:55 a.m. ET
by Ciara Linnane

Boston Scientific sees Q2 adj. EPS 33 cents to 35 cents

Apr. 25, 2018 at 6:54 a.m. ET
by Ciara Linnane

Boston Scientific sees Q2 sales $2.45 bln to $2.50 bln

Apr. 25, 2018 at 6:54 a.m. ET
by Ciara Linnane

Boston Scientific now sees full-year adj. EPS $1.37 to $1.41 vs prior $1.35 to $1.39

Apr. 25, 2018 at 6:54 a.m. ET
by Ciara Linnane

Boston Scientific now sees full-year EPS 90 cents to 94 cents vs prior guidance 93 cents to 98 cents

Apr. 25, 2018 at 6:53 a.m. ET
by Ciara Linnane

Boston Scientific now sees full-year revenue $9.75 bln to $9.90 bln

Apr. 25, 2018 at 6:52 a.m. ET
by Ciara Linnane

Boston Scientific Q1 sales $2.379 bln, up 10.1%; FactSet consensus $2.341 bln

Apr. 25, 2018 at 6:52 a.m. ET
by Ciara Linnane

Boston Scientific Q1 adj. EPS 33 cents; FactSet consensus 32 cents

Apr. 25, 2018 at 6:51 a.m. ET
by Ciara Linnane

Boston Scientific Q1 EPS 21 cents, unchanged vs. year earlier

Apr. 25, 2018 at 6:51 a.m. ET
by Ciara Linnane

Boston Scientific to buy NxThera for up to $406 mln, including $306 mln in upfront cash payment

Mar. 21, 2018 at 6:48 a.m. ET
by Tomi Kilgore

The Amazon chart you may not want to see, but probably should

Feb. 1, 2018 at 9:38 a.m. ET
by Barbara Kollmeyer

Boston Scientific reports Q4 profit, revenue matches

Feb. 1, 2018 at 7:04 a.m. ET
by Emma Court

Boston Scientific expects 2018 adj. EPS of $1.35 to $1.39; FactSet consensus $1.38

Feb. 1, 2018 at 6:54 a.m. ET
by Emma Court

Stryker Makes Takeover Approach to Boston Scientific

Stryker has recently made a takeover approach to rival Boston Scientific, a move that would create a medical-device giant with a combined value of more than $110 billion.

Jun. 11, 2018 at 11:30 a.m. ET
on The Wall Street Journal

In Health Care, Fidelity Targets Secular Growth

Two of the firm’s top health-care funds reject defensive strategies and invest in medical innovation over the long term. Among their picks: Becton Dickinson, Amgen, UnitedHealth, Sarepta Therapeutics, Novartis, Uniqure.

Jun. 1, 2018 at 2:31 p.m. ET
on Barron's Online

Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study

A cardiovascular procedure using devices made by Abbott Laboratories, Johnson & Johnson, Medtronic and Boston Scientific was no better than drug therapy for treating patients with atrial fibrillation, a new study found.

May. 10, 2018 at 6:00 p.m. ET
on The Wall Street Journal

Big Stock Sales: GE, P&G, Pfizer, Bristol-Myers

Alabama pensions manager RSA made cuts in some large caps in Q4. GE was thankfully one of them.

Mar. 14, 2018 at 2:34 p.m. ET
on Barron's Online

Stocks to Watch: Wal-Mart, MoneyGram, Delta, Qualcomm, Netflix, Marriott, J.B. Hunt, Xerox

Jan. 11, 2018 at 9:28 a.m. ET
on The Wall Street Journal

Study Raises Questions About Stents in Some Heart Patients

Nov. 2, 2017 at 6:23 p.m. ET
on The Wall Street Journal

Puerto Rican Businesses Struggle to Restart With Little Power After Hurricane Maria

Oct. 14, 2017 at 7:00 a.m. ET
on The Wall Street Journal

Searching for Missing Workers After the Puerto Rico Storm

Oct. 9, 2017 at 5:33 p.m. ET
on The Wall Street Journal

Boston Scientific Nabs Apama Medical in $300 Million Deal

Oct. 2, 2017 at 7:44 p.m. ET
on The Wall Street Journal

Medtronic: Healthy and Getting Healthier

Aug. 26, 2017 at 1:46 a.m. ET
on Barron's

Medical Tech Bounces Back in Emerging Markets

Aug. 23, 2017 at 3:36 p.m. ET
on Barron's

Endo Settles Most U.S. Claims on Mesh Products

Aug. 7, 2017 at 7:19 p.m. ET
on The Wall Street Journal

Big Medtech Buys May Be Busts

Jun. 21, 2017 at 4:18 p.m. ET
on Barron's

Companies Are Winning the Battle Over Adjusted Earnings

May. 22, 2017 at 8:00 a.m. ET
on The Wall Street Journal

Stocks to Watch: Boston Scientific, Lululemon, McDonald’s

Mar. 30, 2017 at 9:17 a.m. ET
on The Wall Street Journal

Health Insurers Wrestle With Next Steps as GOP Bill Fails

Mar. 24, 2017 at 7:03 p.m. ET
on The Wall Street Journal

Boston Scientific Recalls Lotus Heart Valve Device

Feb. 23, 2017 at 12:57 p.m. ET
on The Wall Street Journal

Stocks to Watch: Hormel Foods, Kohl’s, Tesla

Feb. 23, 2017 at 9:23 a.m. ET
on The Wall Street Journal

Where a Go-Anywhere Fund Is Finding Growth

Feb. 7, 2017 at 11:55 a.m. ET
on Barron's

Sedgwick Losing 15 Partners in Newark, Dallas

Jan. 25, 2017 at 6:21 p.m. ET
on The Wall Street Journal

Other News
Press Releases

Stryker Makes Takeover Approach to Boston Scientific

Stryker has recently made a takeover approach to rival Boston Scientific, a move that would create a medical-device giant with a combined value of more than $110 billion.

Jun. 11, 2018 at 11:30 a.m. ET
on The Wall Street Journal

Analysts’ Ratings for Varian Medical Systems and Peers

Varian Medical Systems (VAR) is engaged in the design, manufacture, sale, and servicing of hardware and software for the treatment of cancer with radiotherapy and radiosurgery.

Jun. 8, 2018 at 6:35 a.m. ET
on MarketRealist.com

Analyzing Varian’s Valuation

In November 2016, Varian Medical Systems' (VAR) board authorized the repurchase of 8 million shares of Varian stock beginning in January 2017.

Jun. 8, 2018 at 6:44 a.m. ET
on MarketRealist.com

How Much Upside Do Analysts See in Baxter Stock?

Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating.

Jun. 8, 2018 at 2:32 p.m. ET
on MarketRealist.com

Boston Scientific (BSX) Presents At Digestive Disease Week Conference - Slideshow

Jun. 5, 2018 at 2:36 p.m. ET
on Seeking Alpha

Abiomed Expected to Report Solid EPS Growth in Fiscal 2019

In the fiscal fourth quarter, Abiomed reported operating margins close to 27.3%, which is a YoY rise of 4.0%.

Jun. 4, 2018 at 6:05 p.m. ET
on MarketRealist.com

Abiomed Expected to Report Robust Revenue Growth in Fiscal 2019

Abiomed generally witnesses a sequential rise in revenues in its fiscal third quarter, driven by higher physician engagement and hospital utilization.

Jun. 4, 2018 at 6:05 p.m. ET
on MarketRealist.com

Analysts’ Recommendations for Abiomed and Peers in May 2018

Of the 11 analysts covering Abiomed in May, five recommended the company as a “strong buy,” and four recommended it as a “buy."

Jun. 4, 2018 at 6:05 p.m. ET
on MarketRealist.com

In Health Care, Fidelity Targets Secular Growth

Jun. 4, 2018 at 3:48 p.m. ET
on Barron's

The SVP & Pres, Eur, Mid-East, Afr of Boston Scientific Corp (BSX) is Selling Shares

Today, the SVP & Pres, Eur, Mid-East, Afr of Boston Scientific Corp (NYSE: BSX), Thepaut ...[...]

May. 18, 2018 at 4:41 p.m. ET
on SmarterAnalyst

Macy's And Micron Ignite A Rally - Cramer's Mad Money (5/16/18)

May. 17, 2018 at 7:48 a.m. ET
on Seeking Alpha

Jim Cramer Gives His Opinion On Boston Scientific, Lennar And Discover Financial

May. 17, 2018 at 6:22 a.m. ET
on benzinga.com

Highlights from Appaloosa's Q1

May. 15, 2018 at 4:42 p.m. ET
on Seeking Alpha

5 Top ROE Stocks to Buy as U.S.-China Trade Concerns Subside

May. 15, 2018 at 12:40 p.m. ET
on InvestorPlace.com

Boston Scientific (BSX) CRM and Electrophysiology Products Overview - Slideshow

May. 14, 2018 at 2:17 p.m. ET
on Seeking Alpha

’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh

May. 14, 2018 at 11:41 a.m. ET
on InvestorPlace.com

Boston Scientific announces real-world data demonstrating success of SMART pass on the S-ICD system

May. 14, 2018 at 8:26 a.m. ET
on Seeking Alpha

Boston Scientific down 2% premarket after critical 60 minutes report

May. 14, 2018 at 7:42 a.m. ET
on Seeking Alpha

Stocks To Watch: A Fed Head Talks Crypto

May. 12, 2018 at 9:16 a.m. ET
on Seeking Alpha

Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study

May. 10, 2018 at 6:00 p.m. ET
on The Wall Street Journal

Vascular Stent Market is Forecast to Cross US$ 4230 Million By 2023

Jun. 11, 2018 at 12:49 p.m. ET
on Heraldkeeper

Stents Market is Forecast to Cross US$ 16.00 Billion By 2024

Jun. 11, 2018 at 12:39 p.m. ET
on Heraldkeeper

Radiofrequency Ablation Devices Market is Determined to Cross US$ 9 Billion By 2023

Jun. 11, 2018 at 12:09 p.m. ET
on Heraldkeeper

Prosthetic Heart Valve Market is Determined to Cross US$ 4 Billion By 2022

Jun. 11, 2018 at 11:59 a.m. ET
on Heraldkeeper

Global Electrosurgical Device Market Business Strategies: Boston Scientific Corporation, Megadyne Medical Products , Medtronic ., KLS Martin LP, Bovie Medical Corporation, Symmetry Surgical

Jun. 11, 2018 at 12:44 a.m. ET
on marketresearch.biz

United States : Readout of HHS Secretary Azars Roundtable with Medical Device Leaders

Jun. 8, 2018 at 6:35 p.m. ET
on Euclid Tenders Info

Neuromodulation Market is Determined to Cross US$ 11 Billion By 2024

Jun. 8, 2018 at 1:06 p.m. ET
on Heraldkeeper

Endoscopy Market is Determined to Cross US$ 36.5 Billion By 2022

Jun. 8, 2018 at 11:54 a.m. ET
on Heraldkeeper

Endoscopy Devices Market is Projected to Reach US$ 33 Billion By 2020

Jun. 8, 2018 at 11:43 a.m. ET
on Heraldkeeper

Diagnostic Catheter Market is Expected to Grow US$ 4.00 Billion By 2022

Jun. 8, 2018 at 11:33 a.m. ET
on Heraldkeeper

Coronary Stent Market is Expected to Grow US$ 10. 00 Billion By 2022

Jun. 8, 2018 at 11:23 a.m. ET
on Heraldkeeper

Cardiac Pacemakers Market is Expected To Be Worth US$ 14 Billion by 2025

Jun. 8, 2018 at 11:13 a.m. ET
on Heraldkeeper

Automated External Defibrillator Market is Forecast to Cross US$ 15 Billion by 2022

Jun. 8, 2018 at 10:53 a.m. ET
on Heraldkeeper

Bio implants Market is Determined to Cross US$ 134 Billion By 2022

Jun. 8, 2018 at 10:53 a.m. ET
on Heraldkeeper

Biopsy Devices Market is Forecast to Cross US$ 2.50 Billion By 2026

Jun. 8, 2018 at 10:53 a.m. ET
on Heraldkeeper

Ablation Devices Market is Forecast to Cross US$ 21 Billion By 2025

Jun. 8, 2018 at 10:43 a.m. ET
on Heraldkeeper

Active Implantable Medical Devices Market is Forecast to Cross US$ 26.5 Billion by 2022

Jun. 8, 2018 at 10:43 a.m. ET
on Heraldkeeper

Cardiac Valve Market Key Insights 2018 | Development and Factors Supporting Growth with Worldwide Key Players | Through the year 2023

Jun. 8, 2018 at 5:37 a.m. ET
on Heraldkeeper

Global Brain Implants Market Business Strategies: St Jude Medical Inc, NDI Medical Inc, Boston Scientific Corporation

Jun. 8, 2018 at 3:52 a.m. ET
on marketresearch.biz

Transcatheter Aortic Valve Replacement Market (TAVR) Growth at CAGR of 14.70% During 2018-2023

Jun. 7, 2018 at 8:58 a.m. ET
on Heraldkeeper

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease, and other cardiovascular disorders including structural heart conditions. The Rhythm Management segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal, and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 26 Full Ratings

Analysts’ Latest Recommendations and Target Prices for Abbott

Apr. 9, 2018 at 11:02 a.m. ET
on MarketRealist.com

Benzinga's Top Analyst Calls From April 5, 2018

Apr. 5, 2018 at 2:44 p.m. ET
on Benzinga.com

Wall Street’s Recommendations for BSX Stock

Apr. 4, 2018 at 12:37 p.m. ET
on MarketRealist.com

Name	Chg %	Market Cap
CONMED Corp.	-0.28%	$2.04B
Merit Medical Systems Inc.	1.02%	$2.48B
AngioDynamics Inc.	0.47%	$783.95M
Stryker Corp.	-3.46%	$66.88B
Teleflex Inc.	0.40%	$12.9B

Competitor Data Provided By

Dow	25,394.34	77.81	0.31%
S&P 500	2,789.34	10.31	0.37%
Nasdaq	7,669.89	24.38	0.32%
GlobalDow	3,077.16	17.19	0.56%
Gold	1,304.60	1.90	0.15%
Oil	66.12	0.38	0.58%

Boston Scientific Corp.

$ 34.99

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers